Prevalence of Transmitted HIV Drug Resistance in Iran between 2010 and 2011

Prevalence of Transmitted HIV Drug Resistance in Iran between 2010 and 2011

OBJECTIVE Drug-resistant (DR) HIV emerges during combined antiretroviral treatment (cART), creating concern about widespread transmission of DR-HIV as cART is expanded in resource-limited countries. The aim of this study was to determine the predominant HIV-1 subtypes and prevalence of transmitted DR mutations among antiretroviral-naïve patients in Iran. DESIGN To monitor transmission of DR H...

Prevalence and patterns of HIV transmitted drug resistance in Guatemala.

OBJECTIVE To assess human immunodeficiency virus (HIV) diversity and the prevalence of transmitted drug resistance (TDR) in Guatemala. METHODS One hundred forty-five antiretroviral treatment-naïve patients referred to the Roosevelt Hospital in Guatemala City were enrolled from October 2010 to March 2011. Plasma HIV pol sequences were obtained and TDR was assessed with the Stanford algorithm a...

Transmitted antiretroviral drug resistance in a low HIV prevalence setting

ii To my family and loved ones iii ACKNOWLEDGMENTS I would like to thank my project mentor Dr. Jeffrey Meier and my thesis supervisor and academic advisor, Dr. Tara Smith as well as the dedicated members of my thesis committee. I owe a debt of gratitude to the staff of the Department of Epidemiology, especially, Amy Sayer, whose guidance has been invaluable and integral to my academic career. i...

Prevalence of Transmitted Drug Resistance and Impact of Transmitted Resistance on Treatment Success in the German HIV-1 Seroconverter Cohort

BACKGROUND The aim of this study is to analyse the prevalence of transmitted drug resistance, TDR, and the impact of TDR on treatment success in the German HIV-1 Seroconverter Cohort. METHODS Genotypic resistance analysis was performed in treatment-naïve study patients whose sample was available 1,312/1,564 (83.9% October 2008). A genotypic resistance result was obtained for 1,276/1,312 (97.3...

HIV treatment decisions and transmitted drug resistance.